Wealth Enhancement Advisory Services LLC Makes New Investment in Twist Bioscience Corporation (NASDAQ:TWST)

Wealth Enhancement Advisory Services LLC acquired a new stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 10,097 shares of the company's stock, valued at approximately $396,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc increased its stake in shares of Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after buying an additional 580 shares during the period. GAMMA Investing LLC increased its stake in shares of Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after buying an additional 303 shares during the period. Banque Transatlantique SA acquired a new position in shares of Twist Bioscience in the fourth quarter valued at approximately $43,000. GF Fund Management CO. LTD. acquired a new position in shares of Twist Bioscience in the fourth quarter valued at approximately $58,000. Finally, US Bancorp DE increased its stake in shares of Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after buying an additional 601 shares during the period.

Insider Activity

In related news, insider Dennis Cho sold 689 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $25,940.85. Following the transaction, the insider directly owned 110,849 shares in the company, valued at $4,173,464.85. This trade represents a 0.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Emily M. Leproust sold 5,042 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $189,831.30. Following the completion of the transaction, the chief executive officer owned 655,432 shares in the company, valued at approximately $24,677,014.80. This represents a 0.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 21,911 shares of company stock worth $761,826. Company insiders own 3.01% of the company's stock.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $38.11 on Monday. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -11.73 and a beta of 2.41. Twist Bioscience Corporation has a 52-week low of $27.12 and a 52-week high of $60.90. The stock's 50 day moving average price is $33.49 and its two-hundred day moving average price is $40.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.24 and a current ratio of 4.51.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The business had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. On average, equities analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on TWST. Guggenheim reiterated a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Barclays reduced their target price on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. The Goldman Sachs Group reduced their target price on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Finally, Robert W. Baird reduced their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and a consensus price target of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.